Ubiquigent Ltd

Ubiquigent Ltd is a biotechnology company founded in 2009 and headquartered in the United Kingdom. The company's slogan is "Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as powerful new therapeutics." Ubiquigent specializes in the discovery and development of novel deubiquitinase (DUB) modulators for areas of high unmet medical need. With 13 years of experience, the company offers a unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). The company is the chosen partner for many leading industry and academic organizations for their drug discovery programs. Their experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. One noteworthy aspect of Ubiquigent is its grant investment received on 14 January 2021 from UK Research and Innovation. The company has an internal pipeline of drug discovery programs and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs), and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialization. Overall, Ubiquigent's focus on developing therapeutics for unmet medical needs and its strong industry partnerships position it as an attractive investment opportunity.